The Impact of Pre-Exposure Prophylaxis on Sexual Communication and Sexual Behavior of Urban Gay and Bisexual Men

被引:0
作者
David W. Pantalone
Ian W. Holloway
Alison E. A. Goldblatt
Kaitlyn R. Gorman
Cara Herbitter
Christian Grov
机构
[1] University of Massachusetts,Department of Psychology
[2] Fenway Health,The Fenway Institute
[3] University of California,Department of Social Welfare
[4] City University of New York Graduate School of Public Health and Health Policy,Department of Community Health and Social Sciences
来源
Archives of Sexual Behavior | 2020年 / 49卷
关键词
Pre-exposure prophylaxis (PrEP); Gay and bisexual men; HIV; Sexual communication; Sexual behavior; Sexual orientation;
D O I
暂无
中图分类号
学科分类号
摘要
Pre-exposure prophylaxis (PrEP) has altered the public health landscape for gay, bisexual, and other men who have sex with men (GBM) by significantly increasing protection against HIV infection. Early epidemiologic data showed GBM generally used PrEP as prescribed, i.e., as an additional protective tool over and above barrier protection, although subsequent reports have been equivocal. Irrespective of population-level trends, some GBM appear to have reevaluated their HIV risk tolerance and changed their interactions with sex partners. Scant published data have focused on factors that influence PrEP-using GBM’s decisions about sexual behavior—including condom use as well as sex with HIV-positive partners—and sexual communication practices. Thus, in this study, we investigated those research concerns qualitatively via content analysis of individual interviews conducted with 103 GBM in New York City (M age 32.5 years, 50% White, 64% on PrEP > 6 months). Emergent themes reflect (1) participants’ strong HIV knowledge; (2) changing GBM community norms about condom use on PrEP; (3) increased focus on risk tolerance with individual differences in post-PrEP condom use; (4) appreciation for routine sexually transmitted infection (STI) screening in PrEP care concomitant with some STI knowledge deficits; (5) decreased stigma concerning, and greater comfort with, HIV-positive sex partners; and (6) increased confidence discussing HIV status and condom use preferences with partners. Findings have implications for future research as well as for clinical practice, such as enhanced STI education and provider-initiated discussions about risk compensation, serosorting, and sexual communication skills.
引用
收藏
页码:147 / 160
页数:13
相关论文
共 257 条
  • [1] Abaasa A(2018)Utility of different adherence measures for PrEP: Patterns and incremental value AIDS and Behavior 22 1165-1173
  • [2] Hendrix C(2012)Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men Science Translational Medicine 4 151ra125-915
  • [3] Gandhi M(2014)Risk compensation in PrEP: An old debate emerges yet again The Virtual Mentor 16 909-1145
  • [4] Anderson P(2011)Motivators, concerns, and barriers to adoption of pre-exposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships AIDS Care 23 1136-657
  • [5] Kamali A(1992)Predictors of condom use in sexually active adolescents Journal of Adolescent Health 13 651-1964
  • [6] Kibengo F(2015)How stigma surrounding the use of HIV pre-exposure prophylaxis undermines prevention and pleasure: A call to destigmatize “Truvada whores” American Journal of Public Health 105 1960-57
  • [7] Haberer JE(2012)Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evidence and evolving questions Current Opinion in Infectious Diseases 25 51-67
  • [8] Anderson PL(2006)Is HIV/AIDS stigma dividing the gay community? Perceptions of HIV-positive men who have sex with men AIDS Education & Prevention 18 56-451
  • [9] Glidden DV(2016)PrEP adherence patterns strongly affect individual HIV risk and observed efficacy in randomized clinical trials Journal of Acquired Immune Deficiency Syndromes 72 444-348
  • [10] Liu A(2014)HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention Journal of Acquired Immune Deficiency Syndromes 66 340-506